Special Issue "Pharmaceutical Functions of Natural Compounds Derived from Molluscs and Arthropods"

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".

Deadline for manuscript submissions: 15 April 2023 | Viewed by 588

Special Issue Editor

Prof. Dr. Pavlina Dolashka
E-Mail Website
Guest Editor
Institute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, 1113 Sofia, str. G. Bonchev 9, Bulgaria
Interests: biochemistry; polysaccharide; glycoproteins; nanoparticle; biomedicine

Special Issue Information

Dear Colleagues,

Molluscs and arthropods are a promising source of bioactive compounds that contribute to favorable adaptations for survival in different environments. Therefore, they are the subject of scientific research with the aim of discovering new antitumor, antimicrobial, and antiviral compounds.

A study of the antitumor properties of active components obtained from hemolymph and mucus demonstrates an antiproliferative effect on cancer cell lines. Compounds in the hemolymph with anticancer activities are hemocyanins, oligomeric oxygen-carrying glycometalloproteins widely used in immunological and clinical applications. These biomacromolecules bind small molecule chemicals, such as drugs, hormones, peptides, polysaccharides, lipids, and oligonucleotides, which, in their pure state, do not elicit a response from the immune system.

Hemocyanins present promising antiviral effects against a number of viruses. The carbohydrate structures and antiviral properties of hemocyanins have been established in the rsearch.

In addition, peptides and glycoproteins with antimicrobial activities against various bacterial strains have been discovered in the hemolymph and mucus of molluscs. They also have a positive effect on neurodegenerative diseases. Due to their broad spectrum of actions, natural antimicrobial peptides are a model for the discovery of new antimicrobial drugs to solve the problem of multidrug resistance in pathogenic microorganisms. Some of the identified biologically active molecules have been developed into pharmaceutical products.

Prof. Dr. Pavlina Dolashka
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glycoproteins
  • antimicrobial peptides
  • nanoparticles
  • therapeutics
  •  mass spectrometry
  • nanodrugs

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Article
Antitumor Activity of Bioactive Compounds from Rapana venosa against Human Breast Cell Lines
Pharmaceuticals 2023, 16(2), 181; https://doi.org/10.3390/ph16020181 - 24 Jan 2023
Viewed by 358
Abstract
This study is the first report describing the promising antitumor activity of biologically active compounds isolated from the hemolymph of marine snail Rapana venosa—a fraction with Mw between 50 and 100 kDa and two structural subunits (RvH1 and RvH2), tested on a [...] Read more.
This study is the first report describing the promising antitumor activity of biologically active compounds isolated from the hemolymph of marine snail Rapana venosa—a fraction with Mw between 50 and 100 kDa and two structural subunits (RvH1 and RvH2), tested on a panel of human breast cell lines—six lines of different molecular subtypes of breast cancer MDA-MB-231, MDA-MB-468, BT-474, BT-549, SK-BR-3, and MCF-7 and the non-cancerous MCF-10A. The fraction with Mw 50–100 kDa (HRv 50–100) showed good antitumor activity manifested by a significant decrease in cell viability, altered morphology, autophagy, and p53 activation in treated cancer cells. An apparent synergistic effect was observed for the combination of HRv 50–100 with cis-platin for all tested cell lines. The combination of HRv 50–100 with cisplatin and/or tamoxifen is three times more effective compared to treatment with classical chemotherapeutics alone. The main proteins in the active fraction, with Mw at ~50 kDa, ~65 kDa, ~100 kDa, were identified by MALDI-MS, MS/MS analyses, and bioinformatics. Homology was established with known proteins with antitumor potential detected in different mollusc species: peroxidase-like protein, glycoproteins Aplysianin A, L-amino acid oxidase (LAAO), and the functional unit with Mw 50 kDa of RvH. Our study reveals new perspectives for application of HRv 50–100 as an antitumor agent used alone or as a booster in combination with different chemotherapies. Full article
Show Figures

Graphical abstract

Back to TopTop